1. Introduction {#sec1}
===============

Multidrug resistant *A. baumannii* constitutes a serious threat for nosocomial infection control \[[@B1]\]. Carbapenems are currently the antibiotics of choice against multidrug-resistant *Acinetobacter* infections \[[@B2]\], but an increasing rate of resistance to carbapenems was reported worldwide, seriously limiting therapeutic options \[[@B3]\]. Carbapenem-resistant *A. baumannii* has become an alarming health care problem, mainly in developing countries \[[@B4]\]. As a result, carbapenem-resistant *A. baumannii* is classified into the critical priority group according to the urgency of need for new antibiotic treatment and the level of reported antibiotic resistance by the World Health Organization \[[@B5]\].

Multiple mechanisms of carbapenem resistance have been identified in *A. baumannii* including low membrane permeability, mutation in its chromosome genes, overexpression of efflux pumps, and acquisition of mobile resistance genes \[[@B6]\]. However, the production of carbapenemases is considered the principal resistance mechanism \[[@B7], [@B8]\]. The most frequent ones are carbapenem-hydrolyzing class D *β*-lactamases (CHDLs) and secondly metalloenzymes (MBL) such as *bla*~NDM~ \[[@B9]\]. In addition, class A *β*-lactamases such as *bla*~KPC~ gene has been recently also detected in *A. baumannii* \[[@B10]\], presenting a serious threat of expanding resistance spectrum in the bacteria.

Currently, six main groups of CHDLs found in *A. baumannii* include *bla*~OXA-51~-like, *bla*~OXA-23~-like, *bla*~OXA-24~-like, *bla*~OXA-58~-like, *bla*~OXA-143~-like, and *bla*~OXA-235~-like genes \[[@B2], [@B11], [@B12]\]. CHDLs exhibit weak carbapenem hydrolysis; however, they can confer resistance mediated by the combination of natural low permeability and IS*Aba* elements located upstream of the gene possibly leading to the gene\'s overexpression \[[@B2]\]. Overexpression of *bla*~OXA~ genes usually corresponds to resistance phenotypes \[[@B13]--[@B15]\]. Overproduction of oxacillinases, including *bla*~OXA-58~ enzyme, results from the presence of insertion sequences such as IS*Aba1*, IS*Aba2*, IS*Aba3*, or IS*18* which provide strong promoters for gene expression \[[@B13], [@B16]\].

In Vietnam, *bla*~OXA-23~ is the most widely disseminated class D-carbapenemase in carbapenem-resistant *Acinetobacter baumannii* while *bla*~OXA-24~ is not detected \[[@B17]\]. Even though there is not any information of *bla*~OXA-143~ and *bla*~OXA-235~ in Vietnam up to now, these genes are believed to emerge in other parts of the world \[[@B18], [@B19]\]. During 2003-2014, the majority of *A. baumannii* clinical isolates recovered harbored *bla*~OXA-51~ and *bla*~OXA-23~ genes. The *bla*~OXA-58~ gene was only detected in isolates recovered from 2010, after the introduction of imipenem in 2008-2009 into hospitals in Vietnam \[[@B17], [@B20]\]. The *bla*~OXA-58~-positive isolates investigated in the present study probably emerged at the same time. This recent emergence was in contrast with the striking replacement of *bla*~OXA-58~ by *bla*~OXA-23~ reported in Italy and China for the same period \[[@B21], [@B22]\]. Furthermore, isolates bearing *bla*~OXA-58~-like gene were recovered from different countries during outbreaks and showed remarkable conserved gene sequence \[[@B23]--[@B25]\]. The aim of this study was to investigate genetic structures and relative expression of *bla*~OXA-58~ gene, which lead to imipenem nonsusceptibility in clinical isolates recovered from two Vietnamese hospitals during 2012-2014.

2. Materials and Methods {#sec2}
========================

2.1. Study Design {#sec2.1}
-----------------

The study focused on *A. baumannii* isolates containing *bla*~OXA-58~ gene with the purpose of determining imipenem-resistance mechanism related to the gene.

2.2. Bacterial Isolates, Microbial Identification, and Antimicrobial Susceptibility Testing {#sec2.2}
-------------------------------------------------------------------------------------------

Five *A. baumannii* isolates were chosen from a total of 252 nonduplicate *Acinetobacter* spp. isolates recovered from patients admitted to hospitals in southern Vietnam during 2012-2014 and were named DN and TN based on their source hospitals \[[@B17]\]. Microbial isolation and identification in source laboratories were performed using the Phoenix System (BD) and the API 20NE system (bioMérieux). Identification of *A. baumannii* isolates was confirmed by PCR amplification and sequencing of 16S-23S intergenic spacer (ITS) regions. The sequences were deposited in GenBank under accession numbers KY659325, KY659326, KY659327, KY659328, and KY659329. Antimicrobial susceptibility testing was performed by the disk diffusion method and interpreted according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2014). Tested antimicrobials included ceftazidime, cefotaxime, ceftriaxone, cefpodoxime, cefepime, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ticarcillin/clavulanic acid, and meropenem, as well as others not belonging to *β*-lactams such as amikacin, gentamicin, ankamycin, netilmicin, ciprofloxacin, and levofloxacin. MIC values of imipenem were determined by the *E*-test (bioMérieux); the CLSI-approved breakpoints for imipenem ≥ 8 *μ*g·ml^−1^ and ≤2 *μ*g·ml^−1^ were considered resistant and susceptible, respectively.

2.3. Detection of *bla*~OXA~, *bla*~NDM~, and *bla*~KPC~ Genes and Insertion Sequences {#sec2.3}
--------------------------------------------------------------------------------------

Amplification of *bla*~OXA~ genes including *bla*~OXA-51~, *bla*~OXA-23~, *bla*~OXA-24~, and *bla*~OXA-58~ genes were performed and published in the previous study \[[@B17]\]. *bla*~NDM~ and *bla*~KPC~ genes were amplified in this study as previously reported \[[@B26]\]. The presence of IS*Aba1*, IS*Aba2*, IS*Aba3*, IS*Aba4*, and IS18 was detected as previously described \[[@B13], [@B27]\]. The sequence of all primers is shown in [Table 1](#tab1){ref-type="table"}.

2.4. PCR Mapping of *bla*~OXA-58~ and *bla*~OXA-51~ Genes {#sec2.4}
---------------------------------------------------------

PCR mapping of *bla*~OXA~ genes upstream regions was carried out using combinations of insertion sequence-specific forward primers and *bla*~OXA-51~ and *bla*~OXA-58~ gene-specific reverse primers ([Table 1](#tab1){ref-type="table"}). The presence of IS*Aba3* downstream of *bla*~OXA-58~ was determined by a long-range PCR containing 1X PrimeSTAR GXL Buffer, 0.2 mmol dNTPs, 500 nmol OXA-58-F, 500 nmol ISAba3C, and 0.5 U PrimeSTAR GXL DNA polymerase (Takara). PCR products were sent to 1-BASE (<https://order.base-asia.com/>) for purification and sequencing. The sequences were analysed by BioEdit 7.0.9.0. (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>), and sequence similarity was assessed using the BLAST program (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The sequence of *bla*OXA-58 and its surrounding IS*Aba3* was deposited in GenBank under accession number KY660721.

2.5. Analysis of *bla*~OXA-58~ and *bla*~OXA-51~ Gene Expression by Real-Time RT-PCR {#sec2.5}
------------------------------------------------------------------------------------

The midlog phase of bacterial cultures was treated with 1 *μ*mol·ml^−1^ oxacillin for 24 h and was subsequently used for RNA extraction \[[@B28]\]. Treatment with RNAse-free DNAse I (Sigma) was performed at 37°C for 2 h. The concentration and DNase-free quality of RNA samples were spectrophotometrically assessed and confirmed by the amplification of chromosomal *bla*~OXA-51~ and 16S rRNA. Fifteen microliters of each RNA sample was reverse-transcribed in a final volume of 20 *μ*l containing random hexamers, MMLV reverse transcriptase (Agilent) at 42^o^ C for 45 min.

Amplification of *bla*~OXA-51~, *bla*~OXA-58~, and 16S rRNA was performed in a final volume of 25 *μ*l containing 5 *μ*l cDNA, 3 mmol MgCl~2~, 200 nmol dNTPs, 2 U h-Taq DNA polymerase (Solgent), 300 nmol of OXA-51/58-F/R primers, 150 nmol of OXA-51/58-P probes, 200 nmol of 16S-F/R primers, and 100 nmol of 16S-P probe (IDT). Primer and probe sequences are given in [Table 1](#tab1){ref-type="table"}. Each real-time PCR was performed in triplicate on the Stratagene Mx3005P real-time PCR system (Agilent). The reaction mixture was incubated for 15 min at 95°C, followed by 40 cycles of 10 s at 95°C and 20 s at 60°C. Normalized expression of *bla*~OXA-51~ and *bla*~OXA-58~ genes was calculated relatively to the 16S rRNA reference gene according to the 2^-*ΔΔ*Ct^ method \[[@B29]\].

2.6. Multiple-Locus Variable Number Tandem Repeat Analysis {#sec2.6}
----------------------------------------------------------

Multiple-locus variable number tandem repeat analysis (MLVA) as previously described \[[@B17], [@B30], [@B31]\] was used to profiling the *A. baumannii* isolates in the study. The method works on eight variable number tandem repeat (VNTR) loci, namely, 3468, 1988, 3002, 845, 2396, 5350, 826, and 2240 to determine relatedness among the *A. baumannii* isolates.

2.7. *β*-Lactamase Extraction and Quantitation {#sec2.7}
----------------------------------------------

Isolates were grown on LB medium supplemented with 1 *μ*mol·ml^−1^ oxacillin for 18-24 h at 37^o^ C in a shaking incubator. The supernatants (extracellular fraction) were collected after centrifugation of bacterial cultures and precipitated with absolute ethanol (1 : 4) in 20 min at -20°C \[[@B32]\]. Periplasmic fractions were recovered from cell pellets \[[@B33]\]. Protein concentration was determined by the Bradford method \[[@B34]\].

*β*-Lactamase activity was determined based on nitrocefin hydrolysis \[[@B35], [@B36]\]. Briefly, 1-5 *μ*l extracellular and periplasmic fractions obtained from each isolate were incubated with 40 nmol nitrocefin dissolved in 0.1 M phosphate buffer, pH 7.0 in a total volume of 100 *μ*l. Samples were loaded onto microtiter plates, and the absorbance at 482 nm was measured kinetically at room temperature for 2-30 minutes using an ELISA spectrophotometer. The specific *β*-lactamase activity was calculated and expressed as mU·mg^−1^ of protein based on the quotient of *β*-lactamase activity (mU·ml^−1^) and protein concentration (mg·ml^−1^).

2.8. Statistical Analysis {#sec2.8}
-------------------------

The analysis of variance (ANOVA) was used to analyse the difference among *β*-lactamase activity means of isolates. A *t*-test was used to determine the significant difference of extracellular and periplasmic *β*-lactamase activity. A *p* value \< 0.05 was considered significant.

3. Results and Discussion {#sec3}
=========================

*bla* ~OXAs~ are prevalent in *A. baumannii*. We had previously performed *bla*~OXA~ identification in *A. baumannii* isolates from three hospitals in Southern Vietnam and found *bla*~OXA-23~ was dominant \[[@B17]\]. Even though *bla*~OXA-58~ existed with a small number in Vietnamese population, the exact genetic context involving antimicrobial resistance elements remained unknown. Here, we uncovered the imipenem-resistance mechanism of *bla*~OXA-58~-positive *A. baumannii* isolates. The overexpression of *bla*~OXA-58~ gene has been seen in the isolate with high-resistance phenotype through relative quantification of mRNA of the corresponding gene. The specific possible-intact IS*Aba3* sequence upstream of *bla*~OXA-58~ gene could be the key factor for the high expression. In addition, the high *β*-lactamase activity in the periplasmic space observed in the study could be the outcome of the phenomenon.

3.1. Antimicrobial Susceptibility Testing {#sec3.1}
-----------------------------------------

All five isolates (DN050, TN078, DN014, TN341, and TN345) were classified as multidrug resistant (MDR) since they were nonsusceptible to at least one agent in three or more antimicrobial categories including aminoglycosides, antipseudomonal carbapenems, antipseudomonal fluoroquinolones, antipseudomonal penicillins and *β*-lactamase inhibitors, extended-spectrum cephalosporins, folate pathway inhibitors, penicillins and *β*-lactamase inhibitors, polymyxins, and tetracyclines \[[@B37]\]. In this study, although several antimicrobials were not tested because of their availableness at different times and hospitals, all isolates satisfied the definition to be defined as MDR. Isolate DNA050 was nonsusceptible to all antimicrobials tested. The other four were all susceptible to imipenem (there were three isolates nonsusceptible to meropenem as hospitals reported), but for other antimicrobials, their susceptibility varied. Isolate TN078 and DN014 were nonsusceptible to three categories while isolates TN341 and TN345 were nonsusceptible to five categories ([Table 2](#tab2){ref-type="table"}).

3.2. Isolate Genotyping and Profiling {#sec3.2}
-------------------------------------

All isolates were identified as *A. baumannii* based on 16S-23S intergenic spacer (ITS) region sequencing. Based on MLVA profiling, four different MLVA types within the five isolates reflected substantial genetic diversity in the sampled Vietnamese *A. baumannii* isolates, as previously described \[[@B17]\].

No isolate with *bla*~KPC~ gene was detected, while two isolates contained *bla*~NDM~ gene (DN050 and TN078). Even though the two isolates were singletons (based on MLVA types from previous study \[[@B17]\]) with different phenotypes, they had close relatedness with just difference in 3/8 loci surveyed and very similar resistance determinants, especially the *bla*~NDM~ gene. Therefore, the difference in resistance phenotype was mostly because of the distinguished genotype with ISAba3\_*bla*~OXA-58~ in isolate DN050, compared to isolate TN078. It might be necessary for *bla*~NDM~ gene located in a specific genetic context to be expressed as one of the important and strong resistance determinants. The mechanism should be explored further.

Regardless of the genetic diversity of the isolates, the *bla*~OXA-58~ gene sequence analysis (data not shown) of all isolates was identical with the reported *bla*~OXA-58~ gene \[[@B38]\]. This was in agreement with a previous work showing a lack of diversity in this gene, probably due to its recent acquisition by *A. baumannii* from other species \[[@B3]\].

All isolates were *bla*~OXA-58~- and *bla*~OXA-51~-positive and *bla*~OXA-23~- and *bla*~OXA-24~-negative ([Table 2](#tab2){ref-type="table"}). The analysis of insertion sequences revealed the presence of IS*Aba1* and IS*Aba2*, but they were not located upstream of *bla*~OXA-51~ nor *bla*~OXA-58~ genes in all isolates. IS*Aba4* and IS18 were not detected. IS*Aba3* was detected in all isolates ([Table 2](#tab2){ref-type="table"}). However, only isolate DN050 possessed a *bla*~OXA-58~ gene bracketed by two IS*Aba3* elements (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). The promoter region of *bla*~OXA-58~ gene in this isolate ([Figure 2](#fig2){ref-type="fig"}) was similar to sequences described by Poirel and Nordmann \[[@B38]\]. The genetic structure of *bla*~OXA-58~ upstream sequences which led to overexpression of this gene displayed a remarkable variability \[[@B38]--[@B40]\]. Hybrid promoters constituting an IS*Aba3* sequence truncated by other insertion sequences were generally considered strong promoters \[[@B22], [@B41]\]. However, in this study, isolate DN050 bearing possible-intact IS*Aba3* sequence upstream of *bla*~OXA-58~ gene was not interrupted by inserted sequences, provided -35 and -10 promoter sequences as already described \[[@B38]\]. This structure probably drove high level carbapenemase production. The acquisition of insertion sequences by an imipenem-susceptible *bla*~OXA-58~ harboring isolate can lead to carbapenem resistance in *A. baumannii* \[[@B38]\]. Our results highlighted the threat of undetected reservoirs of carbapenem-resistant determinants and mechanisms in Vietnamese *A. baumannii* isolates.

3.3. Relative Quantitation of *bla*~OXA-58~ and *bla*~OXA-51~ mRNA Level {#sec3.3}
------------------------------------------------------------------------

We chose three isolates (DN050, TN341, and TN345) to study the relative expression of *bla*~OXA-51~ and *bla*~OXA-58~ under condition with oxacillin as an inducer and without oxacillin induction. They all had high *β*-lactamase activity in periplasmic fractions as shown in the following experiment ([Table 3](#tab3){ref-type="table"}). The mRNA level of *bla*~OXA-58~ and *bla*~OXA-51~ genes in all isolates was determined by quantitative real-time RT-PCR. Under oxacillin induction, DN050 showed a significantly higher level of *bla*~OXA-58~ mRNA expression than isolates TN341 and TN345 ([Figure 3](#fig3){ref-type="fig"}). *bla*~OXA-51~ expression was also upregulated, but not comparable to that of *bla*~OXA-58~. Interestingly, the high expression level of *bla*~OXA-58~ from DN050 could be associated with the presence of an upstream IS*Aba3* sequence as previously suggested \[[@B38]\]. Furthermore, in this study, the possible intact IS*Aba3* sequence might be customized to *bla*~OXA-58~ gene to drive a very strong gene expression, as seen in IS*Aba1* for *bla*~OXA-23~ and AmpC genes \[[@B42]\]. The other isolates lacked upstream IS*Aba3* sequence.

3.4. Analysis of Periplasmic *β*-Lactamase Activity in Association with *bla*~OXA-51/-58~ Relative Expression {#sec3.4}
-------------------------------------------------------------------------------------------------------------

Under the condition of oxacillin induction, the *bla*~OXA-58~ expression of isolate DN050 (MIC~imipenem~ ≥ 32 *μ*g·ml^−1^) was also significantly higher than the expression of other four isolates, TN078, DN014, TNA341, and TN345 with MIC~imipenem~ which were 0.5, 0.19, 0.75, and 0.5, respectively ([Table 3](#tab3){ref-type="table"}). All isolates expressed a low level of *bla*~OXA-51~, confirming that the presence of *bla*~OXA-51~, without an upstream IS*Aba1*, did not confer a resistance phenotype \[[@B16]\]. Furthermore, in variants harboring *bla*~OXA-51~ and *bla*~OXA-58~ genes, carbapenem resistance only correlated with *bla*~OXA-58~ \[[@B43]\], which is in agreement with the results of this study.

The enzyme activity of extracellular fractions was not significantly different (*p* = 0.2187) while one of the periplasmic fractions exhibited a significant difference among isolates (*p* \< 0.0001). Extracellular fractions possessed lower enzyme activity than periplasmic fractions (*p* = 0.0355) in most cases. The periplasmic fraction recovered from all isolates exhibited variable *β*-lactamase activity, with very high activity corresponding to isolate DN050. Isolates TN341 displayed the highest *β*-lactamase activity though weakly expressed *bla*~OXA-58~ gene. This high enzyme activity probably corresponded to other *β*-lactamases responsible for the multidrug resistance phenotypes of the isolate, such as extended-spectrum AmpCs \[[@B44]\]. The presence of other *β*-lactamases could explain the high enzyme activity in periplasmic fractions of the other isolates. Particularly, *bla*~NDM~ gene detected in both isolates DN050 and TN078, but the corresponding *β*-lactamase activities as well as the antimicrobial susceptibilities were different between the two isolates. The mechanism that a strain carrying a *bla*~NDM~ gene is not resistant to carbapenems needs to be discovered further in *A. baumannii*. It might need a unique genetic structure for *bla*~NDM~ gene to be expressed as seen in *K. pneumoniae* \[[@B45]\].

In a transformed *A. baumannii* strain with a *bla*~OXA-58~ plasmid-borne vector, this carbapenemase is selectively released via outer membrane vesicles (OMV) after periplasmic translocation through Sec-dependent system \[[@B32]\]. Furthermore, overexpression of *bla*~OXA-58~ gene increases its periplasmic enzyme concentration and extracellular release leading to efficient carbapenem hydrolysis \[[@B32]\]. The *bla*~OXA-58~ high mRNA level and high periplasmic *β*-lactamase activity of the DN050 isolate in this study suggested a similar overexpression, periplasmic translocation, and release mechanism of *bla*~OXA-58~ carbapenemase, even though our experimental work did not directly show the selection of OMV after being translocated to a periplasmic space. The high periplasmic *β*-lactamase activity of the isolates, especially TN341 in this study, also suggested a possible translocation and release of other *β*-lactamases with a mechanism similar to that identified with *bla*~OXA-58~. Further studies should be carried out to prove the suggested mechanism in clinical isolate similar to the transformed *A. baumannii* strain. To the best of our knowledge, our study is the first report on the overexpression of *bla*~OXA-58~ gene of *A. baumannii* clinical isolates from Vietnam.

This study had some limitations. The first limitation involved the small sample size due to the low prevalence of clinical isolates harboring *bla*~OXA-58~ gene in the population surveyed. The screening has been done in previous studies \[[@B17]\]. Secondly, we did not characterize other resistance mechanisms in *A. baumannii* such as the overexpression of efflux pump genes or existence of multicopy *bla*~OXA-58~ gene \[[@B7], [@B11], [@B46]\]. In addition, the presence of other *β*-lactamase genes such as *bla*~IMP~, *bla*~VIM~, *bla*~GES~, *bla*~OXA-143~, and *bla*~OXA-235~ was not excluded. Furthermore, we did not carry out an alternative experimental approach, such as western blotting against *bla*~OXA-58~ to unequivocally determine if the increase in *β*-lactamase activity is mainly due to this protein.

4. Conclusions {#sec4}
==============

This study identified a mechanism of imipenem resistance related to the overexpression of *bla*~OXA-58~ gene preceded by IS*Aba3* and its corresponding periplasmic enzyme present at high concentration in a multidrug-resistant clinical isolate recovered from a hospital in Vietnam.
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Figure S1: result of imipenem *E*-test for five clinical isolates of A. baumannii (blaOXA-58). Figure S2: electrophoresis results of PCR screening for the presence/absence of ISAba1, ISAba2, ISAba3, ISAba4, and IS18 in five clinical isolates of A. baumannii (blaOXA-58). Figure S3: electrophoresis results of PCR for the presence/absence of insertion sequence (IS) upstream of blaOXA-58 gene. Figure S4: duplex real-time RT-PCR analysis of the blaOXA-51 and blaOXA-58 mRNA relative expression compared with 16S rRNA in five A. baumannii isolates. Figure S5: Bradford assay standard curve of concentration versus absorbance for protein quantification. Figure S6: nitrocefin standard curve. Table S1: duplex real-time RT-PCR analysis of the blaOXA-51 and blaOXA-58 mRNA relative expression in three A. baumannii isolates under conditions with oxacillin as an inducer or without oxacillin induction. Table S2: results for protein quantification of supernatant and periplasmic fractions. Table S3: results for *β*-lactamase activity of supernatant and periplasmic fractions.
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![Genetic structures identified in the IS*Aba3*-*bla*~OXA-58~-positive *A. baumannii* isolate, DN050. IS*Aba3* and *bla*~OXA-58~ genes were indicated by horizontal bold arrows. Horizontal dash lines indicated sequences separating IS*Aba3* and *bla*~OXA-58~. Vertical arrows were for the truncated sites previously reported that did not exist in this isolate. Positions of primers were indicated as referred to [Table 1](#tab1){ref-type="table"} with short thin arrows. The figure is not to scale.](BMRI2020-7213429.001){#fig1}

![Promoter structure of *bla*~OXA-58~ gene from isolate DN050. The -35 and -10 putative promoter sequences and the +1 transcription initiation site within IS*Aba3* are boxed. The *bla*~OXA-58~ start and stop codons, ATG (M) and TAA (∗), respectively, are underlined. Upstream IS*Aba3*/*bla*~OXA-58~ sequences and downstream IS*Aba3*/*bla*~OXA-58~ gene junctions are indicated by arrows. Full sequences obtained are deposited in GenBank (accession number KY660721).](BMRI2020-7213429.002){#fig2}

![Duplex real-time RT-PCR analysis of the *bla*~OXA-51~ and *bla*~OXA-58~ mRNA relative expression in three *A. baumannii* isolates. The error bars represent the deviation for the normalized fold expression of *bla*~OXA-51~ and *bla*~OXA-58~ in three isolates which were positive or negative for the IS*Aba3* upstream of the *bla*~OXA-58~ gene. −: not induced; +: induced.](BMRI2020-7213429.003){#fig3}

###### 

Primers and probes used for PCR amplification and sequencing of antimicrobial resistance genes and related genetic elements.

  Primers/probes   Sequence (5′→3′)                        Length (bp)   Tm (°C)   Product (bp)   Ref.
  ---------------- --------------------------------------- ------------- --------- -------------- -------------------------------
  OXA-23-F         CACTAGGAGAAGCCATGAAGC                   21            55.0      114            Nguyen et al., 2017
  OXA-23-R         CAGCATTACCGAAACCAATACG                  22            55.0                     
  OXA-24-F         GCTAAATGCTTTAATCGGGCTAG                 24            55.0      141            Nguyen et al., 2017
  OXA-24-R         ACTGGAACTGCTGACAATGC                    20            55.0                     
  OXA-51-F         GAAGTGAAGCGTGTTGGTTATG                  22            55.0      148            Nguyen et al., 2017
  OXA-51-R         GCCTCTTGCTGAGGAGTAAT                    20            55.0                     
  OXA-51-P         FAM-CGACTTGGGTACCGATATCTGCATTGC-BHQ1    27            61.3      This study     
  OXA-58-F         ATATTTAAGTGGGATGGAAAGCC                 23            55.0      110            Nguyen et al., 2017
  OXA-58-R         CGTGCCAATTCTTGATATACAGG                 23            55.0                     
  OXA-58-P         FAM-TTTACTTTGGGCGAAGCCATGCAAG-BHQ1      25            60.6      This study     
  16S-rRNA-F       CCAGTGACAAACTGGAGGAAG                   21            55.5      199            This study
  16S-rRNA-R       GCTGTGTAGCAACCCTTTGTA                   21            55.2                     
  16S-rRNA-P       HEX-ACGTCAAGTCATCATGGCCCTTACG-BHQ1      25            61.5                     
  HRF/ISAba1       CACGAATGCAGAAGTTG                       17            56.0      520            Segal et al., 2005
  HRR/ISAba1       CGACGAATACTATGACAC                      18            56.0                     
  ISAba2A          AATCCGAGATAGAGCGGTTC                    20            54.0      1200           Poirel et al., 2006
  ISAba2B          TGACACATAACCTAGTGCAC                    20            52.1                     
  ISAba3A          CAATCAAATGTCCAACCTGC                    20            52.3      200            Poirel et al., 2006
  ISAba3C          AGCAATATCTCGTATACCGC                    20            51.8                     
  ISAba4A          ATTTGAACCCATCTATTGGC                    20            50.6      612            Brown et al., 2007
  ISAba4B          ACTCTCATATTTTTTCTTGG                    20            45.3                     
  IS18A            CACCCAACTTTCTCAAGATG                    20            51.2      925            Poirel et al., 2006
  IS18B            ACCAGCCATAACTTCACTCG                    20            54.7                     
  1512F/ITS        GTCGTAACAAGGTAGCCGTA                    20            54.1      607            Chang et al., 2005
  6R/ITS           GGGTTYCCCCRTTCRGAAAT                    20            56.5                     
  NDM-F            GACCGCCCAGATCCTCAA                      18            55.4      52             Yong et al., 2009; CDC 2011
  NDM-R            CGCGACCGGCAGGTT                         15            57.0                     
  NDM-P            HEX-TGGATCAAGCAGGAGAT-ZEN/IBFQ          17            48.3                     
  KPC-F            GGCCGCCGTGCAATAC                        16            56.0      61             Garcia et al., 2010; CDC 2011
  KPC-R            GCCGCCCAACTCCTTCA                       17            56.5                     
  KPC-P            6FAM-TGATAACGCCGCCGCCAATTTGT-ZEN/IBFQ   23            62.2                     

###### 

*β*-Lactamase susceptibility profiles and genotypes of five *A. baumannii* isolates.

  Isolate                       ID                 DN050                TN078              DN014               TN341               TN345
  ----------------------------- ------------------ -------------------- ------------------ ------------------- ------------------- -------
  Phenotype                     Imipenem           \+                   −                  −                   −                   −
  Meropenem                     \+                 N/A                  \+                 \+                  \+                  
  Ceftazidime                   \+                 \+                   −                  \+                  \+                  
  Cefotaxime                    \+                 \+                   \+                 N/A                 \+                  
  Ceftriaxone                   \+                 \+                   \+                 \+                  \+                  
  Cefpodoxime                   N/A                \+                   N/A                \+                  \+                  
  Cefepime                      \+                 −                    \+                 \+                  \+                  
  Piperacillin                  \+                 N/A                  −                  N/A                 N/A                 
  Ampicillin/sulbactam          \+                 −                    −                  \+                  \+                  
  Piperacillin/tazobactam       \+                 −                    −                  \+                  \+                  
  Ticarcillin/clavulanic acid   N/A                \+                   N/A                \+                  \+                  
  Amikacin                      \+                 \+                   N/A                N/A                 N/A                 
  Gentamicin                    \+                 \+                   N/A                \+                  \+                  
  Ankamycin                     N/A                N/A                  \+                 \+                  −                   
  Netilmicin                    N/A                N/A                  −                  \+                  \+                  
  Ciprofloxacin                 \+                 −                    \+                 \+                  \+                  
  Levofloxacin                  \+                 −                    −                  N/A                 N/A                 
                                                                                                                                   
  Genotype                      *bla* ~OXA-51~     \+                   \+                 \+                  \+                  \+
  *bla* ~OXA-23~                −                  −                    −                  −                   −                   
  *bla* ~OXA-24~                −                  −                    −                  −                   −                   
  *bla* ~OXA-58~                \+                 \+                   \+                 \+                  \+                  
  IS*Aba1*                      \+                 \+                   −                  \+                  −                   
  IS*Aba2*                      \+                 \+                   \+                 −                   −                   
  IS*Aba3*                      \+                 \+                   \+                 \+                  \+                  
  IS*Aba4*                      −                  −                    −                  −                   −                   
  IS18                          −                  −                    −                  −                   −                   
  IS*Aba3*\_*bla*OXA-58         \+                 −                    −                  −                   −                   
  NDM                           \+                 \+                   −                  −                   −                   
  KPC                           −                  −                    −                  −                   −                   
  MLVA profile^∗^               6-0-7-1-17-5-0-3   6-0-7-14-17-6-15-3   9-0-7-1-7-5-14-3   9-0-5-15-15-6-0-2   9-0-5-15-15-6-0-2   

N/A: not determined; −: assay negative (susceptible/absence); +: assay positive (resistant/presence). ^∗^MLVA profile according to the surveyed loci: 3468-1988-3002-845-2396-5350-826-2240.

###### 

Relative quantitation of *bla*~OXA-51~ and *bla*~OXA-58~ mRNA level and *β*-lactamase activity in five *A. baumannii* isolates.

  --------------------------------------------------------------------------------------------------------------------------------
  Isolate                                   DN050           TN078         DN014          TN341         TN345         
  ----------------------------------------- --------------- ------------- -------------- ------------- ------------- -------------
  MIC imipenem (*μ*g·ml^−1^)                ≥32             0.5           0.19           0.75          0.5           

                                                                                                                     

  Relative expression of *bla*~OXA-51~      *Δ*Ct           8.87 ± 0.39   12.87 ± 0.30   7.54 ± 0.66   9.64 ± 0.71   8.80 ± 0.60

  Expression (time)                         1.00\           0.06\         2.51\          0.59\         1.04\         
                                            (0.76-1.31)     (0.05-0.08)   (1.58-3.98)    (0.36-0.96)   (0.69-1.59)   

                                                                                                                     

  Relative expression of *bla*~OXA-58~      *Δ*Ct           4.18 ± 1.18   8.64 ± 0.48    7.99 ± 2.23   8.45 ± 0.53   7.28 ± 0.24

  Expression (time)                         25.69\          1.17\         1.84\          1.33\         3.01\         
                                            (11.3-58.37)    (0.84-1.64)   (0.39-8.61)    (0.93-1.93)   (2.55-3.56)   

                                                                                                                     

  Total *β*-lactamase activity (U·mg^−1^)   Extracellular   10.8 ± 3.3    17.7 ± 5.2     13.9 ± 4.1    10.8 ± 3.3    12.9 ± 3.8

  Periplasmic                               44.7 ± 12.8     15.3 ± 4.3    28.5 ± 8.2     49.6 ± 16.0   27.4 ± 10.0   
  --------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Clara G. de los Reyes-Gavilan
